By Karl Staser, MD, PhD, John F. DiPersio, MD, PhD, William Eades, Angela Goldfain, and Nathan Trujillo, PhD
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the most effective treatment for patients with high risk and relapsed hematologic malignancies. When donor T cells recognize the host as foreign, they induce an immune response against the host and may cause life-threatening graft-versus-host disease (GvHD), a major complication of allo-HSCT. Monitoring T cell subsets pre- and post- transplantation in correlation with patient outcomes may identify the key cell types mediating engraftment, relapse, GvHD, and drug response. Because there are numerous T cell subset populations, many of which are rare, increasing the types that can be detected simultaneously can provide an advantage in unbiased tracking and quantification.